Germline variants and impact on lung cancer outcomes following chemotherapy: A systematic review.

Crit Rev Oncol HematolJun 24, 2026 (epub)
Clinical ResearchOncology (Medical)Medical Genetics

Abdullah R Al-Matrafi, Mark A Baxter, Ewan R Pearson et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the impact of germline genetic variants on chemotherapy outcomes in lung cancer patients of European ancestry. It included 20 studies with 3639 patients, highlighting that variants such as XPD Lys751Gln and ERCC1 C118T are associated with overall and progression-free survival in non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy.

Key findings

  • XPD Lys751Gln and ERCC1 C118T variants are associated with overall survival in NSCLC patients.
  • The review included 20 studies out of 4469 identified, focusing on European ancestry.
  • Insufficient evidence was found for non-platinum-treated NSCLC and SCLC outcomes.

Why it matters

Understanding the role of genetic variants in treatment outcomes can help clinicians tailor chemotherapy regimens for lung cancer patients, potentially improving survival rates and treatment efficacy.

Source

PubMed · PMID 42342141

Published in Crit Rev Oncol Hematol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.